Actavis/Forest Laboratories

Actavis/Forest Laboratories
Deal value:
$25 billion
Deal status: Closed

Before outdoing itself with its $66 billion Allergan ($AGN) buyout, Actavis ($ACT) had the biggest buy of 2014's first half with its acquisition of Forest Labs. And with two deal-minded CEOs at the helm, this one happened quickly.

When the pair first met at 2014's J.P. Morgan Healthcare Conference, then-Actavis CEO Paul Bisaro had already merged Watson Pharmaceuticals with generics maker Actavis and then nabbed Ireland's Warner Chilcott to build up on the branded side. Brand-new Forest CEO Brent Saunders had just stepped into the skipper's chair after Valeant ($VRX) bought up Bausch + Lomb, his former home. And 5 weeks later, they had inked a deal pact.

Carl Icahn

The acquisition further beefed up Actavis' branded offerings, bringing along meds like antidepressant Viibryd and blood-pressure treatment Bystolic. Its constipation remedy, Linzess, complemented a new gastrointestinal portfolio that featured Warner colitis products Asacol and Delzicol.

But according to famed activist investor Carl Icahn, who had long been agitating for a sale of Forest, the deal was more than just a way to even out Actavis' branded and generic offerings; it was a "huge win" for shareholders and "yet another validation of the activist investment philosophy in general," he said in a statement on his website at the time.

For more:
Icahn: Activist investing works, and Forest deal shows it
Actavis inks $25B deal for Forest in bid to build its brand stable
Forest Labs taps ex-Bausch + Lomb chief to replace Solomon as CEO

--Carly Helfand (email | Twitter)

Actavis/Forest Laboratories
Read more on

Suggested Articles

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.